model—the Etiology, Discovery and Experimentation activities designed and implemented by Oncodesign contribute to a more effective approach to the phenomenon of innate and acquired resistance, more effective treatments and a reduction in therapeutic failures.

Working alongside big pharma, biotech’s, public research institutions and investment groups, Oncodesign orients the research and development of new therapeutic and diagnostic tools. Through its range of services, partnerships and licensing programs, Oncodesign’s offering can meet the full range of innovation needs.

Oncodesign is listed on the Euronext Growth Paris market and possesses a stable ownership structure with a majority owner committed to its development.